
Vaxcyte (PCVX) Stock Forecast & Price Target
Vaxcyte (PCVX) Analyst Ratings
Bulls say
Vaxcyte is a clinical-stage vaccine company with a strong product pipeline and unique XpressCF technology, making them well-positioned for success in the expanding PCV market. Their VAX-31 vaccine, with superior serotype coverage and favorable results in clinical trials, sets them apart from competitors like Pfizer's Prevnar 20 and Merck's Capvaxive. With a low market cap and potential for continued growth in the PCV market, Vaxcyte is a promising investment opportunity.
Bears say
Vaxcyte is a clinical-stage vaccine company with financial and regulatory risks due to its long development timelines and potential need for additional capital. Recent decisions by the CDC to recommend fewer vaccinations could also affect the adoption of Vaxcyte's vaccines. However, Vaxcyte's differentiated technology and potential for best-in-class pneumococcal vaccine may drive adoption in the market. There are also potential revenue opportunities in the adult population and several novel RSV vaccines in development.
This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.
Vaxcyte (PCVX) Analyst Forecast & Price Prediction
Start investing in Vaxcyte (PCVX)
Order type
Buy in
Order amount
Est. shares
0 shares